Lushang Freda PharmaceuticalLtd (600223) Stock Overview
Engages in the production and sales of pharmaceuticals, raw materials, and additives in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600223 from our risk checks.
600223 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lushang Freda Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.85 |
| 52 Week High | CN¥9.42 |
| 52 Week Low | CN¥6.46 |
| Beta | 1.38 |
| 1 Month Change | 1.82% |
| 3 Month Change | -6.55% |
| 1 Year Change | 12.30% |
| 3 Year Change | 9.33% |
| 5 Year Change | -21.73% |
| Change since IPO | -11.87% |
Recent News & Updates
Recent updates
We Think That There Are More Issues For Lushang Freda PharmaceuticalLtd (SHSE:600223) Than Just Sluggish Earnings
Mar 31
Lushang Freda Pharmaceutical Co.,Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Mar 25Should You Investigate Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) At CN¥7.74?
Dec 30Many Still Looking Away From Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)
Dec 12Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares
Jun 21Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?
Apr 16Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations
Mar 28Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)
Feb 27Shareholder Returns
| 600223 | CN Personal Products | CN Market | |
|---|---|---|---|
| 7D | 1.8% | 0.4% | -2.4% |
| 1Y | 12.3% | 5.3% | 21.5% |
Return vs Industry: 600223 exceeded the CN Personal Products industry which returned 5.3% over the past year.
Return vs Market: 600223 underperformed the CN Market which returned 21.5% over the past year.
Price Volatility
| 600223 volatility | |
|---|---|
| 600223 Average Weekly Movement | 2.8% |
| Personal Products Industry Average Movement | 4.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 9.3% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 600223 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600223's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 3,630 | n/a | www.lshfreda.com |
Lushang Freda Pharmaceutical Co.,Ltd. engages in the production and sales of pharmaceuticals, raw materials, and additives in China. The company is involved in cosmetics and medicine businesses.
Lushang Freda Pharmaceutical Co.,Ltd. Fundamentals Summary
| 600223 fundamental statistics | |
|---|---|
| Market cap | CN¥7.93b |
| Earnings (TTM) | CN¥224.24m |
| Revenue (TTM) | CN¥3.85b |
Is 600223 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600223 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.85b |
| Cost of Revenue | CN¥1.82b |
| Gross Profit | CN¥2.03b |
| Other Expenses | CN¥1.81b |
| Earnings | CN¥224.24m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 28, 2025
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 52.75% |
| Net Profit Margin | 5.83% |
| Debt/Equity Ratio | 5.0% |
How did 600223 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/21 08:52 |
| End of Day Share Price | 2025/10/21 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lushang Freda Pharmaceutical Co.,Ltd. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhuonan Xu | China International Capital Corporation Limited |
| Yifan Du | Citic Securities Co., Ltd. |
| Hao Jiang | Everbright Securities Co. Ltd. |